Citadel Advisors
NGM

Citadel Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Citadel Advisors’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200
Closed -$318 – 15853
2024
Q1 		$318 Sell
200
-100
-33% -$148 ﹤0.01% 14361
2023
Q4 		$258 Hold
300
– – ﹤0.01% 14072
2023
Q3 		$321 Sell
300
-900
-75% -$1.86K ﹤0.01% 14086
2023
Q2 		$3.11K Buy
1,200
+1,100
+1,100% +$3.92K ﹤0.01% 13719
2023
Q1 		$408 Sell
100
-500
-83% -$2.31K ﹤0.01% 14500
2022
Q4 		$3.01K Sell
600
-22,900
-97% -$144K ﹤0.01% 14261
2022
Q3 		$307K Buy
+23,500
New +$356K ﹤0.01% 9528
2021
Q4 		– Sell
-37,200
Closed -$782K – 15040
2021
Q3 		$782K Buy
+37,200
New +$819K ﹤0.01% 8768

Citadel Advisors's NGM Position: Q2 2024 in Review

Citadel Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 342,195 shares — an estimated $544K sold.

Citadel Advisors first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $15.9M in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.

  • Citadel Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 342,195 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $544K.
  • Citadel Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
  • Citadel Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $15.9M in Q3 2021.
  • 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.